|
‘Molecular Velcro’ may lead to cost-effective alternatives to natural antibodies
Science Daily (press release) Oct. 30, 2013 — Taking inspiration from the human immune system, researchers at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have created a new material that can be programmed to identify an endless variety of … |
|
‘Molecular Velcro’ may lead to cost-effective alternatives to natural antibodies
Science Codex Taking inspiration from the human immune system, researchers at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have created a new material that can be programmed to identify an endless variety of molecules. |
Research and Markets: Competitor Analysis: Staphylococcus aureus Vaccines …Business Wire (press release)Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. Whi…
|
Efficacy and safety of rituximab treatment in early primary Sjogren’s syndrome …
7thSpace Interactive (press release) IntroductionPrimary Sjogren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized, in most cases, by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extra-glandular involvement … |
Rituximab and abatacept but not tocilizumab impair antibody response to …7thSpace Interactive (press release)IntroductionThe objective of the study was to investigate the impact of newer biologic treatments including rituximab, abatacept and tocilizu…
|
Gilead Sciences, Inc. (GILD): Gilead Sciences’ CEO Discusses Q3 2013 Results …
Seeking Alpha This application was supported by data from Study-10109, a single arm open label Phase 2 study of 125 patients who were refractory to both rituximab and alkylating agent chemotherapy. In this study Idelalisib achieved an overall response rate of 54 … Gilead Sciences Announces Third Quarter 2013 Financial ResultsBusiness Wire (press release) |
|
ECTRIMS 2013 – Neues zu Forschung und Therapie für Multiple Sklerose
DMSG Multiple Sklerose Nachrichten Dieses traf u.a. zu auf Alemtuzumab, Peginterferon beta-1a, Laquinimod, Ocrelizumab und Daclizumab. Neuroprotektion (Schutz der Nervenzellen) Das Thema Neuroprotektion spielte eine große Rolle auf dem Kongress. Einer von vielen Ansätzen dazu ist … |
|
Repeat Rituximab Courses Sustain Clinical Efficacy in Patients with RA
Monthly Prescribing Reference SAN DIEGO, CA—A sustained improvement of clinical response was seen after each retreatment course with rituximab in patients with rheumatoid arthritis (RA), with respect to Treat to Target principles and EULAR/ACR recommendations, presented Catalin … |
Biogen Idec Inc (BIIB): Biogen Idec Management Discusses Q3 2013 Results …Seeking AlphaAlso in mid-2014, we look forward to seeing Phase III data for daclizumab in relapsing-remitting MS. Data from the daclizumab Phase IIb registrational study point …
|
The Non-Hodgkin’s Lymphoma Drug Market Will Nearly Double to More Than …
The Providence Journal The Pharmacor advisory service entitled Non-Hodgkin’s Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries’ … |